Insider Selling: Liquidia Co. (NASDAQ:LQDA) CEO Sells $89,468.83 in Stock

Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs sold 8,053 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $89,468.83. Following the completion of the sale, the chief executive officer now owns 812,193 shares of the company’s stock, valued at approximately $9,023,464.23. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Liquidia Stock Performance

NASDAQ:LQDA opened at $11.46 on Friday. Liquidia Co. has a 52 week low of $5.71 and a 52 week high of $16.99. The firm has a market cap of $875.70 million, a price-to-earnings ratio of -7.35 and a beta of 0.22. The firm’s 50-day simple moving average is $10.42 and its 200 day simple moving average is $11.97.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. The business had revenue of $3.66 million for the quarter, compared to the consensus estimate of $7.92 million. Sell-side analysts anticipate that Liquidia Co. will post -1.69 EPS for the current year.

Hedge Funds Weigh In On Liquidia

Several hedge funds have recently bought and sold shares of LQDA. Patient Square Capital LP bought a new position in Liquidia in the 1st quarter valued at about $105,942,000. Farallon Capital Management LLC bought a new position in Liquidia in the 1st quarter valued at about $30,311,000. Sapient Capital LLC bought a new position in Liquidia in the 3rd quarter valued at about $1,336,000. BNP Paribas Financial Markets increased its holdings in Liquidia by 119.4% in the 1st quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock valued at $3,396,000 after buying an additional 125,315 shares during the period. Finally, HighVista Strategies LLC bought a new position in Liquidia in the 2nd quarter valued at about $1,461,000. 64.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

LQDA has been the topic of several research analyst reports. Scotiabank initiated coverage on shares of Liquidia in a research report on Wednesday. They issued a “sector outperform” rating and a $30.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and issued a $25.00 price objective on shares of Liquidia in a research report on Monday, August 19th. HC Wainwright dropped their price objective on shares of Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Oppenheimer initiated coverage on shares of Liquidia in a research report on Tuesday, June 25th. They issued a “market perform” rating on the stock. Finally, Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Liquidia presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).